EP Patent

EP3936143A1 — Treatment of post-bariatric hypoglycemia with exendin (9-39)

Assigned to Leland Stanford Junior University · Expires 2022-01-12 · 4y expired

What this patent protects

Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administer…

USPTO Abstract

Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.

Drugs covered by this patent

Patent Metadata

Patent number
EP3936143A1
Jurisdiction
EP
Classification
—
Expires
2022-01-12
Drug substance claim
No
Drug product claim
No
Assignee
Leland Stanford Junior University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.